Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults: Supplementary data

Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods:
Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length
of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults
(OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among
those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDVinfant
(n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged
<1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in
JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and
OAs.